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Abstract: The outlook for transthyretin amyloidosis (ATTR) is changing with the availability
of new and emerging treatments. ATTR now appears to be more common than previously
thought and is no longer viewed as an obscure diagnosis with a grim prognosis. Now more
than ever, there is growing emphasis on the need for early diagnosis because the treatments
appear to be most effective if started in earlier stages of the disease. Diagnosing ATTR is
a challenge as it may initially present with nonspecific symptoms and it is often thought of as
a diagnosis of exclusion. Increased awareness is imperative as new treatments offer hope and
have the potential to change the disease trajectory. ATTR commonly presents with neurological
and cardiac features. Transthyretin (TTR) is a protein produced in the liver which misfolds either
due to genetic mutations or due to aging and results in deposition of amyloid fibrils in organs and
tissues. Apart from the traditional imaging modalities, newer techniques including echocardio-
graphic strain imaging, magnetic resonance imaging (MRI), and nuclear scintigraphy, as well as
the increased availability of genetic testing are aiding in making a timely diagnosis. In this
review, we present the current understanding of the ATTR disease process, diagnostic and
surveillance approaches, newer treatment modalities, and the future directions.
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Introduction
Transthyretin amyloidosis (ATTR) is a systemic disease with the potential to disrupt the
function of practically every organ of the body. Traditionally, it has been characterized
as affecting peripheral nerves, the gastrointestinal tract, and the heart but even the
central nervous system can be affected as the result of vascular and leptomeningeal
amyloid deposition. Timely and appropriate diagnosis can be relatively difficult
because the initial presenting symptoms may be vague and initially attributed to
other more common conditions. Delays in the diagnosis of ATTR can have serious
consequences for patients who may develop severe end-organ impairment. The devel-
opment of new treatments that appear to be most effective if started early makes it
imperative for clinicians to recognize the constellation of signs and symptoms that may
be clues to the diagnosis of transthyretin amyloidosis.
Amyloidosis is a disease that is confusing to many clinicians, because it does not
indicate a single condition. Rather, amyloidosis is a generic term used to describe the
deposition of misfolded proteins extracellularly in a beta-pleated sheet formation with
resultant impairment of organ and tissue function. Over 30 different proteins have been
demonstrated to form amyloid fibrils.1 The twomost common forms of amyloidosis are
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immunoglobulin light chain amyloidosis (AL) and transthyr-
etin amyloidosis (ATTR).2 The accepted nomenclature for
the different forms of amyloidosis is “A” for amyloid fol-
lowed by the abbreviation of the precursor protein that forms
the amyloid fibrils.1 For example, in ATTR amyloidosis,
transthyretin (TTR) is the precursor protein that forms amy-
loid fibrils and in AL the precursor protein is a monoclonal
immunoglobulin light chain. The clinical course of each
specific type of amyloidosis is determined by the amyloid-
forming protein and the organ predilection. This review will
focus on transthyretin amyloidosis, a form of amyloidosis
that commonly attacks the heart and peripheral nerves.
Transthyretin is predominately made by the liver and
serves as a transport protein for thyroid hormone and reti-
nol/vitamin A. It is also synthesized in small amounts locally
in the central nervous system choroid plexus and ocular retinal
pigment epithelium.2 TTR in blood predominately exists as
a tetramer; however, hereditary destabilizing mutations or
aging can cause disassociation of the tetramer into monomers
which may misfold and deposit as amyloid fibrils.2
Transthyretin amyloidosis can occur either due to
a mutation in the transthyretin gene that is inherited in an
autosomal dominant fashion with variable penetrance or due
to age-related protein misfolding. The current nomenclature
guidelines recommend that familial forms of ATTR, pre-
viously known as familial amyloid polyneuropathy (FAP) or
familial amyloid cardiomyopathy (FAC), now be called her-
editary ATTR (hATTR) and the description of the predomi-
nant features and mutation should also be included if known.
For example, a hATTR patient with a mutation at position 30
could be described as having ATTRVal30Met with cardio-
myopathy (CM), neuropathy, or mixed phenotype.2 The age-
related form of amyloidosis primarily affects the heart and is
called wild-type amyloidosis (ATTRwt, formally known as
senile cardiac amyloidosis) to indicate that wild-type or nor-
mal transthyretin protein can form amyloid fibrils.
Over 100 different mutations in transthyretin have been
described.2 Clinical manifestations often correlate with the
specific point mutation.2 Certain mutations are traditionally
thought to present clinically with a neurologic phenotype with
progressive peripheral sensory-motor polyneuropathy while
others present with restrictive heart failure.2 However, there
may be substantial overlap of organ involvement and many
mutations present with a mixed phenotype with features of
both neuropathy and cardiomyopathy (Figure 1). Certain
mutations are endemic in different areas of the world and
ethnicities so it is important to understand a patient’s ancestral
heritage. The most prevalent TTR mutation worldwide is the
Val30Met mutation and ATTR classically presents with per-
ipheral neuropathy.2 In the United States, the most common
hereditary mutation is Val122Ile and organ involvement may
be limited to the heart. The Val122Ile mutation in transthyretin
is present in 3–4% of African Americans in the United States,
but ATTR may have variable penetrance.2
The age-related form of amyloidosis primarily affects the
heart and is called wild-type amyloidosis and abbreviated
ATTRwt (formally known as senile cardiac amyloidosis) to
indicate that wild-type or normal transthyretin protein can
form amyloid fibrils.2 ATTRwt is more common in men and
individuals over age 60. The exact cause of ATTRwt and
reasons for male predominance are unknown.
Diagnostic Approach
It is not unusual that patients have been evaluated by several
physicians with no satisfactory explanation of their symptoms
or concerns. The two most common presenting signs and
symptoms of ATTR amyloidosis are peripheral neuropathy
and/or congestive heart failure and therefore should be
Figure 1 In hereditary transthyretin amyloidosis point mutations in the transthyretin gene can lead to a predominately neurologic or cardiac phenotype, however, there is
often substantial overlap and a mixed phenotype with both neurologic and cardiac features is common.
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included in the differential diagnosis of both conditions. It is
important for the clinician to look for the underlying cause of
peripheral neuropathy or congestive heart failure to make
a specific diagnosis before labeling the conditions as “idio-
pathic.” It is important to remember that CHF, atrial fibrilla-
tion, and peripheral neuropathy are not diagnoses, they are
symptom complexes. They do not clinically “get to the heart”
of the matter. Common misdiagnoses for ATTR polyneuro-
pathy include chronic demyelinating polyneuropathy (CIDP),
Charcot Marie Tooth, Guillain Barré, idiopathic axonal neuro-
pathy, lumbar spinal stenosis, motor neuron disease, diabetic
neuropathy, and alcoholic polyneuropathy.5 ATTR cardio-
myopathy is oftenmisdiagnosed as hypertensive heart disease,
hypertrophic cardiomyopathy, or undifferentiated heart failure
with preserved ejection fraction.3 A comprehensive history
and physical, family history, laboratory studies, cardiac ima-
ging, neurologic testing, genetic testing, and biopsies of
affected organs are often needed to differentiate between
these other conditions and confirm a diagnosis of ATTR
amyloidosis.
Although the nerves and heart are most commonly
affected in ATTR amyloidosis, other organ systems such as
the central nervous system and gastrointestinal tract may also
be impacted. Therefore, leptomeningeal ATTR amyloidosis
should be included in the differential diagnosis of strokes,
intracranial hemorrhage, and episodes of loss of conscious-
ness. Additionally, gastrointestinal ATTR amyloidosis should
be included in the differential diagnosis of early satiety,
alternating constipation and diarrhea, unintentional weight
loss which might be ascribed to Crohn’s disease, irritable
bowel syndrome, and progressive systemic sclerosis.
Integrating the History, Physical,
and Test Results: Red Flags for
Transthyretin Amyloidosis
One sign or symptom alone is often not sufficient to make the
diagnosis of ATTR amyloidosis unless there is a known
hereditary mutation. It is often necessary to integrate many
signs and symptoms that may raise the suspicion for ATTR
amyloidosis. Red flags for transthyretin amyloidosis may
include multisystem organ involvement, bilateral carpal tun-
nel syndrome, spinal stenosis, a discordance between the
electrocardiogram (ECG) voltage and wall thickness seen
on cardiac imaging, orthostatic hypotension, intolerance to
standard heart failure medications such as angiotensin-
receptor enzyme inhibitors (ACE inhibitors) and beta-
blockers, paradoxical low flow/low gradient aortic stenosis,
alternating diarrhea and constipation, and unexplained per-
ipheral neuropathy (Figure 2).3,4
Imaging clues for cardiac involvement may include an
apical sparing pattern on global longitudinal strain on
echocardiography with an apical-to-basal strain ratio
>2.1, diffuse subendocardial late gadolinium enhancement
or increased extracellular volume on MRI, and increased
uptake of the bone avid tracers technetium 99m technetium
pyrophosphate (99mTc-PYP), 99mTc 3,3-disphonphone-
1,2-propanodicarboxylic acid (99mTc-DPD), or 99m tech-
netium hydroxymethylene diphosphate (99mTc99-HMDP)
on nuclear bone scintigraphy.3,4
Neurologic clues may include carpal tunnel syndrome,
progressive axonal polyneuropathy or dysautonomia.
Amyloidosis should be included in the differential diag-
nosis of peripheral neuropathy associated with autonomic
involvement, especially in patients without diabetes.5
Additionally, cardiomyopathy or neuropathy associated
with symptoms of other organ involvement should raise
suspicion for transthyretin amyloidosis.5
Transthyretin Amyloid
Cardiomyopathy
Pathophysiology of Cardiac ATTR
Deposition of amyloid fibrils in the heart leads to an
increase in global wall thickness which makes the heart
Figure 2 Red Flags for Transthyretin Amyloidosis.
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less compliant and leads to diastolic heart dysfunction.
Initially, the left ventricular ejection fraction (LVEF) is
preserved despite a reduction in the LV cavity volume
and effective stroke volume because the ratio of the left
ventricular stroke volume to left ventricular end-diastolic
volume (LVEF) remains normal. In more advanced disease
the LVEF may become reduced. An LVEF < 50% portends
an ingravescent clinical course. Amyloid fibrils are inert
and do not conduct electricity very well so there may be
a discordance between the left ventricular wall thickness
on cardiac imaging and the ECG voltage. Amyloid fibrils
deposit in the atria, ventricular myocardium, conduction
system, and valves leading to atrial and ventricular
arrhythmias, heart block, electromechanical dissociation,
atrial thrombi, and valvular thickening.
Diagnosis of Cardiac ATTR
Cardiac amyloidosis is more common than previously
thought and is likely underdiagnosed. A prospective study
performed in 2015 that included 120 patients admitted to
the hospital over age 60, with heart failure with preserved
ejection fraction (EF > 50%) and a left ventricular wall
thickness ≥12 mm found that 13% of patients had moderate
to severe uptake of 99mTc-DPD.6 TTR genetic testing was
performed in all patients with positive scans and was found
to be negative in all cases suggesting a diagnosis of wild-
type transthyretin amyloidosis. Additionally, in older
patients with calcific aortic stenosis up to 15% of patients
have wild-type ATTR amyloidosis and up to 30% of
patients with low flow low gradient aortic stenosis may
have ATTR amyloidosis.7
Left ventricular hypertrophy without a long history of
hypertension may be a clue to an infiltrative cardiomyo-
pathy. In patients with unexplained left ventricular hyper-
trophy (wall thickness >1.4 cm) on cardiac imaging, first
see if there is a discordance between the ECG voltage and
wall thickness on cardiac imaging.4 Then obtain a detailed
history that focuses on any past history of bilateral carpal
tunnel syndrome, vitreous opacities, spinal stenosis, neu-
ropathy, diarrhea and constipation, erectile dysfunction,
and a family history of heart failure. Do not dismiss the
fact that a personal or family history of heart attack or
sudden death may have been CHF or cardiac arrhythmias
due to amyloidosis. The physical exam should focus on
evaluation for vitreous opacities, clinical evidence of con-
gestive heart failure, and sensory and motor neuropathy
(deep tendon reflexes, vibration sense, light touch, muscle
strength). You also want to evaluate for signs and
symptoms of Immunoglobulin Light Chain amyloidosis
(AL) which may present with periorbital purpura, macro-
glossia, congestive heart failure, hepatomegaly, and per-
ipheral neuropathy.
It can sometimes be difficult to differentiate between
the different types of amyloidosis based on the history and
physical examination and imaging studies. The two most
common forms of amyloidosis that can affect the heart are
ATTR and AL (95% of cases), but there are less common
forms that can affect the heart as well (ex. ApoA1, immu-
noglobulin heavy chain, fibrinogen alpha chain, and gelso-
lin). AL amyloidosis with cardiac involvement is
considered a medical emergency because death may
occur within 6 months if untreated and should be ruled
out in all patients with suspected cardiac amyloidosis. The
following laboratory tests should be obtained to evaluate
for AL amyloidosis: serum free light chains, serum protein
electrophoresis (SPEP) and urine protein electrophoresis
(UPEP) with immunofixation, and a urinalysis to look for
proteinuria. If the lab work reveals an abnormal ratio of
serum kappa and lambda free light chains (less than 0.26
or greater than 1.65), a hematology consult and/or bone
marrow biopsy may be required.3
Once AL amyloidosis has been ruled out in patients with
findings concerning for cardiac amyloidosis, either a biopsy
or nonbiopsy diagnosis of ATTR can be made. Diagnosis
without biopsy can be made by obtaining a nuclear scinti-
graphy scan using 99mTc-PYP, 99mTc-DPD, or 99mTc-
HMDP.3 These bone tracers are known to have high uptake
in the heart with ATTR amyloidosis. 99mTC-PYP is the
bone tracer that is most commonly used in the United
States.3
If the nuclear scan is positive and shows more uptake of
tracer in the heart than the bone, this would be suggestive of
a diagnosis of ATTR amyloidosis as long as AL amyloidosis
has been ruled out. Genetic testing should then be performed
to evaluate for a genetic mutation in TTR. If a known patho-
logic mutation in TTR is found the presumptive diagnosis is
hereditary ATTR. Alternatively, if the DNA analysis is nor-
mal and the patient has a positive nuclear scintigraphy scan,
the diagnosis would be wild-type ATTR. Alternatively, car-
diac biopsy can be performed to make the diagnosis of
amyloidosis.3 The benefit of a biopsy diagnosis is that the
amyloid can be specifically typed by mass spectrometry or
immunohistochemistry to determine the specific amyloid-
forming protein. If ATTR amyloidosis is confirmed on biopsy
this should again be followed by genetic testing (Figure 3).
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Treatment of ATTR CM
Nonspecific treatment for ATTR-CM should focus on
volume management with diuretics and control of arrhyth-
mias. Standard therapy for heart failure with reduced ejec-
tion fraction such as angiotensin-converting enzymes,
angiotensin-receptor blockers, beta-blockers, and angio-
tensin-receptor blockers-neprilysin inhibitors may not be
well tolerated due to hypotension.2 Specific treatments for
ATTR cardiomyopathy fall under the general categories of
synthesis inhibitors of TTR protein by the liver either by
liver transplantation or gene silencers, TTR tetramer sta-
bilizers, and fibril disrupters (Figure 4).2
Since the majority of TTR is made by the liver, liver
transplant can prevent the production of mutant TTR in
patients with hereditary ATTR. Liver transplantation has
been most effective in patients with the Val30Met mutation
with early onset of disease that is limited to peripheral neuro-
pathy. The FAPWTR registry reports there have been 2236
liver transplants for ATTR performed as of December 31,
2017. Important prognostic factors are modified body mass
index, duration of the symptoms (<7 years), age (<50 years),
absence of amyloid cardiomyopathy, and degree of autonomic
involvement.8 Although liver transplantation can prevent the
production of mutant TTR, once organs have been “seeded”
with mutant TTR, normal or wild-type TTR may continue to
form amyloid fibrils. Emerging new medical therapies may
soon replace liver transplant and as such in the last few years
there has been a decline in the reported number of transplant
patients in the registry.
In ATTR cardiomyopathy the left ventricular cavity is
small with thick walls causing restrictive cardiomyopathy
with low cardiac output. As a result, mechanical circulatory
support is not beneficial in end-stage congestive heart failure.9
Heart transplant may be considered in severe ATTR cardio-
myopathy with limited extracardiac involvement but will not
slow the progression of the disease in other organs. Patients
Figure 3 Diagnosis of Transthyretin Amyloid Cardiomyopathy. It is essential to first consider and rule out Immunoglobulin Light Chain Cardiac Amyloidosis, before doing
more specific testing for transthyretin amyloidosis.
Abbreviations: AL, immunoglobulin light chain amyloidosis; ATTR, transthyretin amyloidosis; Apo, apolipoprotein; SPEP, serum protein electrophoresis; UPEP, urine
protein electrophoresis; Tc, technetium; MGUS, monoclonal gammopathy of unknown significance.
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with the Val122Ile mutation often have disease primarily
limited to the heart so isolated heart transplantation may be
appropriate.2 In certain mutations, combined heart and liver
transplant is an option. More than 50 cases of combined heart
and liver transplantation have been reported so far, however,
due to the advances in medical therapy, the numbers of liver
transplantation will likely decrease. AL cardiac amyloidosis
typically has a poor prognosis with a median survival of about
7.1 months. In carefully selected patients, with recent
advances in chemotherapy, initial high dose chemotherapy
followed by heart transplant and subsequent autologous
bone marrow transplant has resulted in better outcomes.9
The two drugs approved for hereditary ATTR poly-
neuropathy that have been shown to slow or improve
neuropathy are inotersen (Tegsedi,™ Akcea Therapeutics,
Boston, MA, USA) and patisiran (Onpattro,™ Alnylam
Pharmaceuticals, Cambridge, MA, USA).10,11 Both drugs
decrease the synthesis of mutant and wild-type TTR by the
liver. Many patients with hereditary ATTR have a mixed
phenotype and have both neuropathy and cardiomyopathy.
While not a primary end point of these trials, imaging and
functional data suggest that these drugs may also stabilize
or reverse hereditary ATTR cardiomyopathy.12,13
Patisiran is administered intravenously every 3 weeks with
pretreatment with steroids and Benadryl to offset drug
reactions.10 Second generation formulations of inotersen and
patisiran are currently being studied prospectively in
hereditary and wild-type ATTR cardiomyopathy. The second
generation of patisiran will be administered subcutaneously
every 3 months and is being studied in the Helios B trial
(Alnylam Pharmaceuticals, Cambridge, MA, US) in ATTR
hereditary and wild-type cardiomyopathy. The CARDIO-
TTRansform trial (Ionis Pharmaceuticals, Carlsbad, CA, US
and Akcea Therapeutics, Boston, MA, US) will study
a modified form of inotersen which is anticipated to have
less side effects and is administered subcutaneously once per
month in hereditary and wild-type ATTR cardiomyopathy.
Revusiran (Alnylam Pharmaceuticals, Cambridge, MA,
US) is a subcutaneous small interfering RNA that was studied
prospectively in patients with hereditary ATTR cardiomyopa-
thy in the ENDEAVOR trial, but the trial was stopped prema-
turely at 6.7 months by the sponsor due to increased deaths in
the treatment arm. Eighteen patients (12.9%) died in the
revusiran arm and 2 patients (3%) died in the placebo arm.14
The sponsor was unable to identify a drug-related mechanism
to explain the increased mortality in the revusiran group.14,15
Tafamidis (Vynaqel,™ Pfizer, New York, NY, US),
Diflunisal, and AG10 are stabilizers of the TTR tetramer that
inhibit dissociation into monomers and fibril formation.
Tafamidis is the first FDA approved therapy for wild-type
and hereditary ATTR cardiomyopathy. The ATTR-ACT
study showed that daily administration of tafamidis 20 mg or
80 mg decreased all-cause mortality, cardiovascular hospitali-
zations, and decreased the decline in 6-minute walk distance
Figure 4 Treatment for Transthyretin Amyloidosis.
Abbreviations: siRNA, small interfering RNA; TUDCA, tauroursodeoxycholic acid.
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and quality of life compared to placebo at 30 months.16
NYHA class I and II patients received the greatest benefit,
suggesting that early identification and treatment are essential.
Tafamidis, however, is priced at $225,000/year and is the most
expensive cardiovascular drug ever marketed in the United
States.17 A recent cost-effective analysis of tafamidis sug-
gested that the price would have to be reduced by 92.6% to
be considered cost-effective and more accessible to patients.17
Diflunisal is a nonsteroidal anti-inflammatory drug that has
been shown to reduce the progression of ATTR polyneuro-
pathy compared to placebo in a randomized, double-blind trial
with 130 patients.18 Diflunisal has been used off label to treat
ATTR cardiomyopathy, but must be used with caution in heart
failure patients as it may exacerbate heart failure or negatively
affect renal function. A retrospective analysis of 81 patients
with ATTR cardiomyopathy treated with diflunisal for
a median of 1 year showed a statistically significant increase
in serum TTR concentration, a decrease in left atrial volume
index, and serum troponin I. More long-term data are needed,
but diflunisal may represent a cost-effective tetramer stabilizer
in ATTR cardiomyopathy.19 The efficacy of the tetramer sta-
bilizer AG10 (Eidos Therapeutics, San Francisco, CA, USA)
is currently being studied prospectively in the randomized
double-blind ATTRibute-CM trial.
Alternative therapies that may disrupt fibril formation,
but for which more data are needed include doxycycline,




Pathophysiology of ATTR Polyneuropathy
Amyloid deposits first in the endoneurial blood vessels lead-
ing to degeneration of Schwann cells as well as the blood-
nerve barrier. It is thought that small unmyelinated nerve
cells are impacted first so in early disease myelin fiber
density and nerve conduction velocity studies (NCV)/elec-
tromyogram (EMG) remain normal, despite the patient
experiencing symptoms of loss of pain and temperature
sensation.20 Patients may also present with autonomic symp-
toms early in the disease course due to amyloid deposition in
autonomic ganglia. Later in the disease course, there is addi-
tional disruption of Schwann cells and amyloid deposition in
the dorsal root ganglia with resultant demyelination and
distal axon deterioration.20 Amyloid deposition may also
occur within the blood vessel walls and lumens. As the
disease progresses patients develop length-dependent loss
of sensory and later motor weakness that can be interpreted
on NCVand EMG as a large fiber peripheral neuropathy.20
Diagnosis of Hereditary ATTR
Polyneuropathy
Initial symptoms of hereditary ATTR polyneuropathy may
include distal sensory symptoms such as numbness, pain and
paresthesias in the feet, autonomic dysfunction, early satiety,
diarrhea and constipation, erectile dysfunction, and weight
loss. As the disease advances the neuropathy may ascend to
include not only the lower limbs but also the upper extremities,
and result in loss of motor function, deep tendon reflexes,
muscular weakness, and gait disorders.5,20 Hereditary ATTR
polyneuropathy is endemic in Brazil, Japan, Sweden, and
Portugal. The prevalence in endemic countries is approxi-
mately 1 in 1000.5 In endemic countries, ATTR polyneuropa-
thy should be considered in patients with length-dependent
small-fiber polyneuropathy with autonomic dysfunction,
family history of ATTR amyloidosis, renal dysfunction, vitr-
eous opacities, heart arrhythmias, and/or unexplained weight
loss. ATTR amyloidosis can also occur in nonendemic coun-
tries due to sporadic mutations. The worldwide prevalence of
hereditary ATTR polyneuropathy is estimated to be 1 in
1,000,000.5
Nerve conduction studies and EMGs are performed to
detect the presence of peripheral neuropathy. The diagnosis
of hereditary ATTR polyneuropathy can be confirmed in
patients with polyneuropathy with genetic testing of the TTR
gene and a biopsy demonstrating amyloid deposits. Biopsies
may be obtained from salivary glands, abdominal fat pad,
nerve tissue, skin, kidney, or gastrointestinal tract.5 Positive
Congo red staining of the biopsy with apple-green birefrin-
gence under polarized light can confirm a diagnosis of amy-
loidosis. Mass spectroscopy or immunohistochemistry can
then be used to type the amyloid-forming protein (Figure 5).
Many patients with hereditary ATTR polyneuropathy also
have cardiomyopathy so bone scintigraphy with 99m
technetium pyrophosphate, 99mtechnetium 3,3-disphon-
phone-1,2-propanodicarboxylic acid, or 99m technetium
hydroxymethylene diphosphate scan or an endomyocardial
cardiac biopsy can be performed to confirm cardiac
involvement.
Medical Treatment of Hereditary ATTR
Polyneuropathy
There are two FDA approved drugs for the treatment of
hereditary ATTR polyneuropathy, inotersen (Tegsedi™,
Dovepress Benson et al
Therapeutics and Clinical Risk Management 2020:16 submit your manuscript | www.dovepress.com
DovePress
755
Akcea Therapeutics, Boston, MA, US) and patisiran
(Onpattro™, Alnylam Pharmaceuticals, Cambridge, MA,
US).10,11 Both drugs inhibit the production of TTR by the
liver and have been shown to slow progression and/or
improve polyneuropathy. Inotersen is a 2′-O-methoxyethyl–
modified antisense oligonucleotide that is administered via
subcutaneous injection. The modified neurologic impairment
score +7 and Norfolk Quality of Life Scale favored therapy
with inotersen compared to placebo in preventing the pro-
gression of neuropathy and maintaining quality of life.11
Treatment-emergent side effects included severe thrombocy-
topenia and glomerulonephritis and rejection in patients with
liver transplantation. These side effects are manageable with
routine monitoring. Patients receiving inotersen require
weekly monitoring of platelet counts, biweekly monitoring
of serum creatinine, estimated glomerular filtration rate,
urine protein to creatinine ratio and urinalysis plus periodic
monitoring of liver function. Patients are also required to take
vitamin A supplementation during treatment. Treatment
should not be initiated in patients with a platelet count less
than 100,000/mm3 or a history of glomerulonephritis related
to inotersen. A trial is currently underway to evaluate the
safety and tolerability of a second-generation antisense oli-
gonucleotide therapeutic administered subcutaneously every
Figure 5 Diagnosis of Transthyretin Amyloid Polyneuropathy.
Abbreviations: CNS, central nervous system; EMG, electromyography; NCS, nerve conduction study.
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4 weeks (AKCEA-TTR-LRx) that is anticipated to have less
side effects.
Patisiran (Onpattro,™Alnylam Pharmaceuticals, Boston,
MA, USA) is a small interfering RNA that is administered
every 3 weeks intravenously with pretreatment with steroids
and Benadryl.10 Patisiran was studied in the APOLLO trial
which showed stabilization or improvement in the modified
Neurologic Impairment Score and Norfolk Quality of Life
Scale. Adverse reactions in the patisiran group that were
more common than placebo included peripheral edema
(30% vs 22%) and infusion-related reactions (19% vs 9%).
Vitamin A supplementation is recommended. No routine
safety monitoring is required. The Helios A study is currently
in progress to evaluate the safety and efficacy of a second-
generation subcutaneous formulation (vutrisiran) adminis-
tered every 12 weeks.
Tafamidis (Vynadqel,™ Pfizer, New York, NY, US) is
a TTR tetramer stabilizer that was approved for hereditary
stage I neuropathy in Europe but did not receive FDA
approval in the United States for treatment of peripheral
neuropathy.21,22 Diflunisal is a nonsteroidal anti-
inflammatory drug that has been shown to slow neuropathy
in a randomized double-blind study involving 130 patients
but approval from the FDA for this condition has not been
pursued.18
Conclusion
Transthyretin amyloidosis is thought to be underdiagnosed.
Because of the multi-system involvement, clinicians must
often integrate clues from the patient’s personal and family
history, physical exam, cardiac imaging, neurologic testing,
genetic testing, and ophthalmologic and gastrointestinal
findings to make a diagnosis. Screening should be consid-
ered in patients with unexplained left ventricular hypertro-
phy or peripheral neuropathy. Additionally, transthyretin
amyloidosis should be considered in older patients with
heart failure with preserved ejection fraction or aortic ste-
nosis. The currently available treatments appear to be most
effective if started early, so making a timely diagnosis is
essential.
Future Directions
There is currently a significant amount of research in the field
of ATTR amyloidosis that will undoubtedly affect diagnosis
and treatment. Earlier diagnosis of this fatal disease will
hopefully improve survival and quality of life. New nonin-
vasive techniques are being developed to diagnose ATTR
amyloidosis at earlier stages. Additionally, new therapeutic
approaches may focus on gene editing and methods to
remove amyloid deposition from affect organs and reverse
end-organ damage.
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